贝伐珠单抗治疗非小细胞肺癌脑转移

Bevacizumab in the treatment of non-small cell lung cancer with brain metastases

肺癌脑转移的发生影响患者预后，抗血管生成治疗成为继手术、全脑放疗、立体定位放疗和化疗之后肺癌脑转移患者新的治疗选择。贝伐珠单抗作为一种抗血管生成药物，具有较好的控制瘤周水肿的作用。研究表明，贝伐珠单抗联合化、放疗治疗非小细胞肺癌脑转移具有较好的疗效及安全性。

The occurrence of brain metastases in lung cancer affects the prognosis of patients. Follow- ing surgery, whole brain radiotherapy, stereotactic radiotherapy and chemotherapy, anti-angiogenesis therapy has become a new treatment option for lung cancer patients with brain metastases. As an anti-angiogenic drug, bevacizumab has a better effect of controlling peritumoral edema. Studies have shown that bevacizumab combined with chemotherapy, radiotherapy to treat non-small cell lung cancer with brain metastasis has a good efficacy and safety.